The efficacy of N-acetylcysteine in reversing nitrate tolerance has been controversial. This study examined whether continuous administration of N-acetylcysteine, a sulfhydryl compound, can prevent the development of tolerance to nitroglycerin; its acute effects on developed tolerance were also assessed. Rats were treated with subcutaneous injections of 1) 100mg/kg nitroglycerin,2) 100mg/kg nitroglycerin and 700mg/kg N-acetylcysteine, 3 times a day for 3 days. The sensitivity to nitroglycerin was studied in aortic preparations. The degree of developed tolerance to nitroglycerin was partially inhibited by simultaneous injection of N-acetylcysteine. Subsequent in vitro preincubation of aortic strips with nitroglycerin (10-5M) reduced the subsequent nitroglycerin sensitivity of vessels from rats treated with nitroglycerin and N-acetylcysteine; sensitivity returned to the initial control level after in vitro preincubation with N-acetylcysteine. The nitroglycerin sensitivity of vessels from rats treated only with nitroglycerin, though, was not affected by in vitro preincubation with N-acetylcysteine. In conclusion, N-acetylcysteine is not effective in reversing the high degree of tolerance developed to nitroglycerin. However, continuous administration of Nacetylcysteine is effective in preventing the development of nitroglycerin tolerance.
3) Concentration-response curves were constructed again to assess the effects of nitroglycerin preincubation.
4) The vessels were washed for 30min and then incubated for 10min with N-acetylcysteine (10-5M).
5) After washing, concentration-response curves were determined to assess the effects of N-acetylcysteine preincubation. 
RESULTS
Initial dose-response relation for nitroglycerin: evidence for induction of nitroglycerin tolerance:
The vessels from TNG group rats showed a reduced sensitivity to nitroglycerin as compared with control group rats, indicating the development of tolerance to the drug. The sensitivity to nitroglycerin of the vessels from TNG+NAC group rats was intermediate, indicating a partial inhibition of induced tolerance (Fig.1 ). There were significant differences between the ED50 values (-log[molar concentration]) for the 3 groups (Table I) .
Changes in the sensitivity to nitroglycerin caused by in vitro preincubation with nitroglycerin and N-acetylcysteine:
In the control and TNG groups, there were no differences in the ED50 values in the serial dose-response curves under different preincubation conditions (Figs.2 and 3 ). In the TNG+NAC group, though, preincubation for 5min with 10-5M nitroglycerin reduced the sensitivity of the aortic rings to nitroglycerin.
However, subsequent preincubation with N-acetylcysteine Jpn. Heart J. (10-5M) turned the nitroglycerin sensitivity to the first control level (Fig.4) .
The ED50 values for the 3 serial dose response curves are shown in Table I tinuous nitroglycerin infusion in patients with congestive heart failure. It was also reported that tolerance to nitroglycerin in the coronary vascular bed could be partially reversed by N-acetylcysteine.11) In contrast, induced tolerance to isosorbide dinitrate was not reversed by administration of Nacetylcysteine in patients with angina pectoris.12) However, the question of whether N-acetylcysteine can prevent the development of nitrate tolerance has not been examined. Only a single clinical study in patients with unstable angina15) showed that combined use of nitroglycerin and N-acetylcysteine reduced the incidence of acute myocardial infarction, but not the frequency of episodes of chest pain. And this reduction in the frequency of acute myocardial infarction was attributed to the potentiated antiplatelet effect of nitroglycerin by N-acetylcysteine.
The present animal study demonstrated that simultaneous administration of N-acetylcysteine and nitroglycerin to rats partially prevented the development of nitrate tolerance. This inhibition of the development of tolerance was reversed by preincubation of arterial strips in a high concentration of nitroglycerin.
Further, subsequent preincubation with N-acetylcysteine returned the sensitivity to the initial (prenitroglycerin) control level. On the other hand, N-acetylcysteine preincubation did not affect the nitrate tolerance of vessels from rats that had received only nitroglycerin prior to preparation of arterial strips.
A current hypothesis is that organic nitrate such as nitroglycerin reacts with sulfhydryl groups to form nitrous acid which is converted to nitric oxide. curves for nitroglycerin were constructed, so the possibility of an extracellular interaction between N-acetylcysteine and nitroglycerin can be excluded. The nitroglycerin dose administered in the present study (300mg/kg/ day) was the same as used in animal studies in rats.3),7) Clinically, continuous intravenous injection of nitroglycerin amounts at most to 15mg/kg/ day. The N-acetylcysteine dose used in this study was 2,100mg/kg/day, which exceeds the dose used clinically (200-300mg/kg/day).15),26) The concentration used in vitro for preincubation with N-acetylcysteine was 10-5M, this concentration approximately corresponds to the plasma concentration associated with clinical N-acetylcysteine therapy.27), 28) A recent report29) showed that some patients developed early tolerance to a continuous intravenous infusion of nitroglycerin, while others had a persistent response as assessed by changes in pulmonary artery wedge pressure. The present results imply that individual variability in the basal level of sulfhydryl groups may contribute to individual differences in the development of nitrate tolerance.
In conclusion, to prevent the development of nitrate tolerance and to maintain the effectiveness of nitrate therapy, continuous supplementation of sulfhydryl groups is recommended.
Because of the high dose of N-acetylcysteine and nitroglycerin used in the present study, our observation may not be directly applicable to a clinical setting. Further studies are needed to evaluate the clinical use of continuous N-acetylcysteine administration.
